Skip to main content
Rafael Holdings, Inc. logo

Rafael Holdings, Inc. — Investor Relations & Filings

Ticker · RFL ISIN · US75062C1009 US Professional, scientific and technical activities
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-07-22 Director's Dealing
Country US United States of America
Listing US RFL

About Rafael Holdings, Inc.

https://rafaelholdings.com

Rafael Holdings, Inc. is a clinical-stage biotechnology company that invests in and develops therapies for difficult-to-treat diseases. The company holds interests in early-stage and clinical pharmaceutical entities, with a primary focus on novel cancer therapeutics aimed at improving and extending the lives of patients. Following a merger with Cyclo Therapeutics, Rafael Holdings is also advancing a potential breakthrough treatment for Niemann-Pick Type C1, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
3
Director's Dealing
2025-07-22 English
CURRENT REPORT
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the election of a new ex-officio director, amendments to the company's bylaws, and related corporate governance changes. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document focuses on management and board changes and governance amendments. Therefore, the most appropriate classification is 'Board/Management Information' (MANG). The document length (6681 characters) supports that this is a substantive filing rather than a brief announcement or certification.
2025-07-18 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Rafael Holdings, Inc. It registers shares of common stock reserved for issuance under equity incentive plans. The document references the Securities Act of 1933 and includes detailed information about the plans, shares registered, and legal opinions. It is not a financial report, earnings release, or management discussion. It is a registration statement related to securities issuance under employee benefit plans, which is a type of capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the registration statement itself, not just an announcement.
2025-06-26 English
4
Director's Dealing
2025-06-24 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes references to Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits), typical of an 8-K filing. It contains a press release about a clinical study update and does not include comprehensive financial statements or detailed financial analysis. The document length is 5251 characters, which is relatively short and consistent with a current report rather than a full annual or quarterly report. The presence of a press release as an exhibit further supports this classification. Therefore, the filing type is Regulatory Filings (RNS), as 8-Ks are general regulatory announcements that do not fit into other specific categories like Annual Report or Interim Report.
2025-06-18 English
4
Director's Dealing
2025-06-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.